Vanguard Portfolio Management
BCRX icon

Vanguard Portfolio Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Vanguard Portfolio Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111M Sell
11,139,158
-105,467
-0.9% -$954K 0.01% 1467
2026
Q1 		$107M Buy
+11,244,625
New +$87.3M 0.01% 1422

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management's BCRX Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 0.94% in Q2 2026, selling an estimated $954K and leaving 11,139,158 shares worth $111M. The position accounts for 0.01% of the portfolio, ranked #1467.

Vanguard Portfolio Management first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. 315 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Vanguard Portfolio Management held 11,139,158 shares of BioCryst Pharmaceuticals worth $111M as of Q2 2026.
  • Vanguard Portfolio Management sold 105,467 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $954K.
  • BioCryst Pharmaceuticals made up 0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1467 holding.
  • Vanguard Portfolio Management first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 315 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.